{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CML", "JAK2/STAT3", "MAPK", "PI3K/Akt/mTOR", "apoptosis", "cycle arrest", "flavagline"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35959422", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "15"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "08", "Day": "04"}], "Language": ["eng"], "ELocationID": ["10.2147/DDDT.S357891"], "Journal": {"ISSN": "1177-8881", "JournalIssue": {"Volume": "16", "PubDate": {"Year": "2022"}}, "Title": "Drug design, development and therapy", "ISOAbbreviation": "Drug Des Devel Ther"}, "ArticleTitle": "The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways.", "Pagination": {"StartPage": "2545", "EndPage": "2557", "MedlinePgn": "2545-2557"}, "Abstract": {"AbstractText": ["Chronic myelogenous leukemia (CML) is a hematological malignancy with increased proliferation of cells of the myeloid series. This can disrupt normal hematopoiesis. The 1-(2-(dimethylamino)acetyl)-rocaglaol (MQ-16) is a new synthetic flavagline compound that showed promising activity in chronic myeloid leukemia K562 cells. This study aims to analyze the underlying mechanisms of MQ-16 against CML.", "Growth, cell cycle progression, and apoptosis were assessed in K562 cells following MQ-16 exposure by MTT assay and flow cytometry. The effect of MQ-16 on DNA strands between nucleosomes was examined by 1% agarose gel electrophoresis. PI3K/Akt/mTOR, JAK2/STAT3, and mitogen-activated protein kinase (MAPK) pathway-related proteins were detected in MQ-16-treated K562 cells by Western blot.", "MQ-16 significantly inhibited the proliferation of K562 cells and arrested the cell cycle at the G2/M phase in a time- and concentration-dependent manner. MQ-16 induced mitochondria-dependent apoptosis by downregulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and induced time- and concentration-dependent DNA fragmentation. In addition, MQ-16 affected the expression of PI3K/Akt/mTOR, JAK2/STAT3, and MAPK pathway-related proteins.", "In summary, MQ-16 appears to be a promising chemotherapeutic drug for treating CML."], "CopyrightInformation": "\u00a9 2022 Yang et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "Stem Cell and Tissue Engineering Research Center, Guizhou Medical University, Guiyang, 550004, People's Republic of China."}], "LastName": "Yang", "ForeName": "Xinmei", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Laboratory, The Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang, 550023, People's Republic of China."}], "LastName": "Wu", "ForeName": "Xijun", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "FuRong Tobacco Research Station, Xiangxi Autonomous Prefecture Tobacco Company Yongshun Branch, Yongshun, 416700, People's Republic of China."}], "LastName": "Wu", "ForeName": "Xiaosen", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}], "LastName": "Huang", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}], "LastName": "Song", "ForeName": "Jingrui", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}], "LastName": "Yuan", "ForeName": "Chunmao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stem Cell and Tissue Engineering Research Center, Guizhou Medical University, Guiyang, 550004, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Pediatrics, Affiliated Hospital of Guizhou Medical University, Guiyang, 550001, People's Republic of China."}], "LastName": "He", "ForeName": "Zhixu", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guizhou Medical University, Guiyang, 550014, People's Republic of China."}], "LastName": "Li", "ForeName": "Yanmei", "Initials": "Y"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Drug Des Devel Ther", "NlmUniqueID": "101475745", "ISSNLinking": "1177-8881"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Benzofurans"}, {"RegistryNumber": "0", "NameOfSubstance": "STAT3 Transcription Factor"}, {"RegistryNumber": "0", "NameOfSubstance": "STAT3 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "rocaglaol"}, {"RegistryNumber": "EC 2.7.1.1", "NameOfSubstance": "MTOR protein, human"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "JAK2 protein, human"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Janus Kinase 2"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "TOR Serine-Threonine Kinases"}, {"RegistryNumber": "EC 2.7.11.24", "NameOfSubstance": "Mitogen-Activated Protein Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Benzofurans"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Janus Kinase 2"}, {"QualifierName": [], "DescriptorName": "K562 Cells"}, {"QualifierName": ["genetics"], "DescriptorName": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"}, {"QualifierName": ["metabolism"], "DescriptorName": "Mitogen-Activated Protein Kinases"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": ["metabolism"], "DescriptorName": "STAT3 Transcription Factor"}, {"QualifierName": ["metabolism"], "DescriptorName": "TOR Serine-Threonine Kinases"}], "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. doi:10.3322/caac.21654", "ArticleIdList": ["10.3322/caac.21654", "33433946"]}, {"Citation": "Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87\u2013100.", "ArticleIdList": ["27595359"]}, {"Citation": "Bartram CR, Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277\u2013280. doi:10.1038/306277a0", "ArticleIdList": ["10.1038/306277a0", "6580527"]}, {"Citation": "Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447\u20131459. doi:10.1016/S0140-6736(13)62120-0", "ArticleIdList": ["10.1016/S0140-6736(13)62120-0", "25484026"]}, {"Citation": "Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u2013984. doi:10.1038/s41375-020-0776-2", "ArticleIdList": ["10.1038/s41375-020-0776-2", "PMC7214240", "32127639"]}, {"Citation": "Hehlmann R. Chronic myeloid Leukemia in 2020. Hemasphere. 2020;4(5):e468. doi:10.1097/HS9.0000000000000468", "ArticleIdList": ["10.1097/HS9.0000000000000468", "PMC7544304", "33134861"]}, {"Citation": "Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391\u20134402. doi:10.1002/cncr.30864", "ArticleIdList": ["10.1002/cncr.30864", "PMC5673547", "28743165"]}, {"Citation": "Paritala V, Chiruvella KK, Thammineni C, et al. Phytochemicals and antimicrobial potentials of mahogany family. Rev Bras Farmacogn. 2015;25:61\u201383."}, {"Citation": "Ebada SS, Lajkiewicz N, Porco JA Jr, et al. Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae). Prog Chem Org Nat Prod. 2011;94:1\u201358. doi:10.1007/978-3-7091-0748-5_1", "ArticleIdList": ["10.1007/978-3-7091-0748-5_1", "PMC4157394", "21833837"]}, {"Citation": "Kim S, Salim AA, Swanson SM, et al. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem. 2006;6(4):319\u2013345. doi:10.2174/187152006777698123", "ArticleIdList": ["10.2174/187152006777698123", "16842234"]}, {"Citation": "Ribeiro N, Thuaud F, Nebigil C, et al. Recent advances in the biology and chemistry of the flavaglines. Bioorg Med Chem. 2012;20(6):1857\u20131864. doi:10.1016/j.bmc.2011.10.048", "ArticleIdList": ["10.1016/j.bmc.2011.10.048", "22071525"]}, {"Citation": "Uzawa K, Kasamatsu A, Saito T, et al. Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects. Exp Cell Res. 2019;376(2):210\u2013220. doi:10.1016/j.yexcr.2019.01.016", "ArticleIdList": ["10.1016/j.yexcr.2019.01.016", "30690028"]}, {"Citation": "Hausott B, Greger H, Marian B. Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells. Int J Cancer. 2004;109(6):933\u2013940. doi:10.1002/ijc.20033", "ArticleIdList": ["10.1002/ijc.20033", "15027128"]}, {"Citation": "Yuan G, Chen X, Liu Z, et al. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45\u03b1 pathway. J Exp Clin Cancer Res. 2018;37(1):21\u201332. doi:10.1186/s13046-018-0695-5", "ArticleIdList": ["10.1186/s13046-018-0695-5", "PMC5804081", "29415747"]}, {"Citation": "Song J, Yuan C, Yang J, et al. Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. FEBS J. 2018;285(24):4631\u20134645. doi:10.1111/febs.14690", "ArticleIdList": ["10.1111/febs.14690", "30387554"]}, {"Citation": "Burgers LD, F\u00fcrst R. Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation. Pharmacol Res. 2021;170:105535. doi:10.1016/j.phrs.2021.105535", "ArticleIdList": ["10.1016/j.phrs.2021.105535", "34058326"]}, {"Citation": "Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell. 2002;109(2):97\u2013107. doi:10.1016/S0092-8674(02)00704-3", "ArticleIdList": ["10.1016/S0092-8674(02)00704-3", "11983156"]}, {"Citation": "Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417. doi:10.1038/s41571-020-0341-y", "ArticleIdList": ["10.1038/s41571-020-0341-y", "PMC8211386", "32203277"]}, {"Citation": "Fresno Vara J\u00c1F, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193\u2013204. doi:10.1016/j.ctrv.2003.07.007", "ArticleIdList": ["10.1016/j.ctrv.2003.07.007", "15023437"]}, {"Citation": "Venugopal S, Bar-Natan M, Mascarenhas JO. JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia. Blood Rev. 2020;40:100634. doi:10.1016/j.blre.2019.100634", "ArticleIdList": ["10.1016/j.blre.2019.100634", "31677846"]}, {"Citation": "Kim EK, Choi E-J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396\u2013405. doi:10.1016/j.bbadis.2009.12.009", "ArticleIdList": ["10.1016/j.bbadis.2009.12.009", "20079433"]}, {"Citation": "Yang HJ, Li YN, Yan C, et al. Discovery and synthesis of rocaglaol derivatives inducing apoptosis in HCT116 cells via suppression of MAPK signaling pathway. Fitoterapia. 2021;151:104876. doi:10.1016/j.fitote.2021.104876", "ArticleIdList": ["10.1016/j.fitote.2021.104876", "33675885"]}, {"Citation": "Yang J, Qiu J, Hu Y, et al. A natural small molecule induces megakaryocytic differentiation and suppresses leukemogenesis through activation of PKC\u03b4/ERK1/2 signaling pathway in erythroleukemia cells. Biomed Pharmacother. 2019;118:109265. doi:10.1016/j.biopha.2019.109265", "ArticleIdList": ["10.1016/j.biopha.2019.109265", "31545282"]}, {"Citation": "Chen X, Song J, Yuan D, et al. Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/AKT pathway in benign prostatic hyperplasia. Biosci Rep. 2021;41(6):BSR20210477. doi:10.1042/BSR20210477", "ArticleIdList": ["10.1042/BSR20210477", "PMC8220449", "34100062"]}, {"Citation": "Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014;55(9):1980\u20131992. doi:10.3109/10428194.2013.855307", "ArticleIdList": ["10.3109/10428194.2013.855307", "PMC4152229", "24295132"]}, {"Citation": "Xiao W, Li B, Sun X, et al. DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma. Acta Biochim Biophys Sin. 2018;50:643\u2013650. doi:10.1093/abbs/gmy047", "ArticleIdList": ["10.1093/abbs/gmy047", "29688264"]}, {"Citation": "Zhu M, Shi X, Gong Z, et al. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020;158:104868. doi:10.1016/j.phrs.2020.104868", "ArticleIdList": ["10.1016/j.phrs.2020.104868", "32407961"]}, {"Citation": "Xiao Y, Deng T, Wang D. Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway. J BUON. 2020;25:1607\u20131613.", "ArticleIdList": ["32862611"]}, {"Citation": "Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u2013542. doi:10.1016/j.ccell.2020.03.006", "ArticleIdList": ["10.1016/j.ccell.2020.03.006", "PMC7722523", "32289275"]}, {"Citation": "Callahan KP, Minhajuddin M, Corbett C, et al. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014;28(10):1960\u20131968. doi:10.1038/leu.2014.93", "ArticleIdList": ["10.1038/leu.2014.93", "PMC4148474", "24577530"]}, {"Citation": "Sancar A, Lindsey-Boltz LA, Unsal-Ka\u00e7maz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73(1):39\u201385. doi:10.1146/annurev.biochem.73.011303.073723", "ArticleIdList": ["10.1146/annurev.biochem.73.011303.073723", "15189136"]}, {"Citation": "Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332(2):237\u2013248. doi:10.1016/j.canlet.2012.01.007", "ArticleIdList": ["10.1016/j.canlet.2012.01.007", "22261329"]}, {"Citation": "Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(4):297\u2013308. doi:10.1038/nrm2351", "ArticleIdList": ["10.1038/nrm2351", "18285803"]}, {"Citation": "Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20\u201333. doi:10.1038/nrc.2015.2", "ArticleIdList": ["10.1038/nrc.2015.2", "26678314"]}, {"Citation": "Liu K, Zheng M, Lu R, et al. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell Int. 2020;20(1):213\u2013228. doi:10.1186/s12935-020-01304-w", "ArticleIdList": ["10.1186/s12935-020-01304-w", "PMC7268735", "32518522"]}, {"Citation": "Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15(6):122\u2013131. doi:10.1186/gb4184", "ArticleIdList": ["10.1186/gb4184", "PMC4097832", "25180339"]}, {"Citation": "Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770\u20131783. doi:10.1200/JCO.2005.03.7689", "ArticleIdList": ["10.1200/JCO.2005.03.7689", "16603719"]}, {"Citation": "Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12(9):440\u2013450. doi:10.1016/j.molmed.2006.07.007", "ArticleIdList": ["10.1016/j.molmed.2006.07.007", "16899408"]}, {"Citation": "Dixon SC, Soriano BJ, Lush RM, et al. Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother. 1997;31(1):76\u201382. doi:10.1177/106002809703100113", "ArticleIdList": ["10.1177/106002809703100113", "8997471"]}, {"Citation": "Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging. 2016;8(4):603\u2013619. doi:10.18632/aging.100934", "ArticleIdList": ["10.18632/aging.100934", "PMC4925817", "27019364"]}, {"Citation": "Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205\u2013219. doi:10.1016/S0092-8674(04)00046-7", "ArticleIdList": ["10.1016/S0092-8674(04)00046-7", "14744432"]}, {"Citation": "Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175\u2013193. doi:10.1038/s41580-018-0089-8", "ArticleIdList": ["10.1038/s41580-018-0089-8", "PMC7325303", "30655609"]}, {"Citation": "Thomberry NA, Laxebnik Y. Caspases: enemies within. Science. 1998;281(5381):1312\u20131316. doi:10.1126/science.281.5381.1312", "ArticleIdList": ["10.1126/science.281.5381.1312", "9721091"]}, {"Citation": "Gourley C, Balma\u00f1a J, Ledermann JA, et al. Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37(25):2257\u20132269. doi:10.1200/JCO.18.02050", "ArticleIdList": ["10.1200/JCO.18.02050", "31050911"]}, {"Citation": "McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22(4):708\u2013722. doi:10.1038/leu.2008.27", "ArticleIdList": ["10.1038/leu.2008.27", "18337766"]}, {"Citation": "An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u20131268. doi:10.1016/j.leukres.2010.04.016", "ArticleIdList": ["10.1016/j.leukres.2010.04.016", "20537386"]}, {"Citation": "Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22(4):686\u2013707. doi:10.1038/leu.2008.26", "ArticleIdList": ["10.1038/leu.2008.26", "18337767"]}, {"Citation": "Vogt PK, Hart JR, Gymnopoulos M, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol. 2010;347:79\u2013104. doi:10.1007/82_2010_80", "ArticleIdList": ["10.1007/82_2010_80", "PMC2955792", "20582532"]}, {"Citation": "Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120\u2013128. doi:10.1016/j.gene.2019.02.076", "ArticleIdList": ["10.1016/j.gene.2019.02.076", "30849534"]}, {"Citation": "Vachhani P, Bose P, Rahmani M, et al. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics. 2014;46(13):448\u2013456. doi:10.1152/physiolgenomics.00173.2013", "ArticleIdList": ["10.1152/physiolgenomics.00173.2013", "PMC4080281", "24824212"]}, {"Citation": "Vitagliano O, Addeo R, D\u2019Angelo V, et al. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol. 2013;6(5):587\u2013597.", "ArticleIdList": ["24083449"]}, {"Citation": "De Luca A, Maiello MR, D\u2019Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17\u201327. doi:10.1517/14728222.2011.639361", "ArticleIdList": ["10.1517/14728222.2011.639361", "22443084"]}, {"Citation": "Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270(5240):1326\u20131331. doi:10.1126/science.270.5240.1326", "ArticleIdList": ["10.1126/science.270.5240.1326", "7481820"]}, {"Citation": "Jing L, Anning L. Role of JNK activation in apoptosis: a doubleedged sword. Cell Res. 2005;15:36\u201342. doi:10.1038/sj.cr.7290262", "ArticleIdList": ["10.1038/sj.cr.7290262", "15686625"]}, {"Citation": "Long Q, Xiao X, Yi P, et al. L20, a Calothrixin B analog, induces intrinsic apoptosis on HEL cells through ROS/\u03b3-H2AX/p38 MAPK pathway. Biomed Pharmacother. 2021;137:111336. doi:10.1016/j.biopha.2021.111336", "ArticleIdList": ["10.1016/j.biopha.2021.111336", "33550048"]}, {"Citation": "Shi Y, Zhang Z, Qu X, et al. Roles of STAT3 in leukemia (review). Int J Oncol. 2018;53(1):7\u201320. doi:10.3892/ijo.2018.4386", "ArticleIdList": ["10.3892/ijo.2018.4386", "29749432"]}, {"Citation": "Pilati C, Zucman-Rossi J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev. 2015;26:499\u2013506. doi:10.1016/j.cytogfr.2015.07.010", "ArticleIdList": ["10.1016/j.cytogfr.2015.07.010", "26188635"]}, {"Citation": "Liu C, Zeng Y, Dai LH, et al. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Am J Cancer Res. 2015;5(4):1308\u20131318.", "ArticleIdList": ["PMC4473312", "26101699"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "1", "Day": "20"}, {"Year": "2022", "Month": "6", "Day": "27"}, {"Year": "2022", "Month": "8", "Day": "12", "Hour": "3", "Minute": "13"}, {"Year": "2022", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["35959422", "PMC9359389", "10.2147/DDDT.S357891", "357891"]}}], "PubmedBookArticle": []}